CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients-Reference-Cited by-同舟云学术

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

Published:2023-06-13 Issue:8 Volume:62 Page:1129-1139
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

van Eerden Ruben A. G.^ORCID,IJzerman Nikki S.,van Meekeren Milan,Oomen-de Hoop Esther,Guchelaar Niels A. D.,Visser Andrea M. W.,Matic Maja,van Schaik Ron H. N.,de Bruijn Peter,Moes Dirk-Jan A. R.,Jobse Pieter A.,Gelderblom Hans,Huitema Alwin D. R.,Steeghs Neeltje,Mathijssen Ron H. J.,Koolen Stijn L. W.^ORCID,

Funder

de Merel Stichting

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-023-01260-4.pdf

Reference36 articles.

1. Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441–64.

2. Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, et al. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012;97(5):731–8.

3. Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909–16.